Contraire mes amis. This is a big data company in a extremely competitive sector. Our competitors include long established labs and clinics, hospitals, universities and other genomic testing concerns. Add to this list the testing Instrument providers. Then you can include Big Data like IBM who are offering their services.
Listen to the last conference call and the issues of competition and fee reimbursement are prominent.
On a side note your moniker is offensive to me as one who served our Country as JK has. What service to our great Republic did you give?.
As far as I know, the drop has been systemic for all bio/pharma and health care and a rotation out of the sectors.
Further to you being remiss for not selling higher you're not alone. I discussed this this topic with someone who is crazy wealthy. The topic centered around when does greed interfere with a frank appraisal of value. Neither one of us could come-up with a answer.
There used to be authentic discussions on the state of the company. Sure, I had many disagreements but for the most part it was based on the OPK game plan. Now all I read are pumpers and terrorists spewing their meaningless dung. Grow-up and lets discuss the why and if's.